Dexlansoprazole Pellets
Dual delayed-release pellets targeting extended acid suppression, ideal for once-daily GERD control with staged gastric release.
Dexlansoprazole Pellets - pharmaceutical overview
Dexlansoprazole Pellets – Dual Delayed-Release Multiparticulate Technology for PPI Formulations. Rraynex Dexlansoprazole Pellets are engineered for dual delayed-release pharmaceutical formulations requiring sequential release characteristics. The multiparticulate system uses controlled layering and enteric protection to support reproducible dissolution and extended acid-suppression formulations for pharmaceutical manufacturers. Overview: Dexlansoprazole is a proton pump inhibitor and the R-enantiomer of lansoprazole. Its DDR formulation is designed around two delayed-release phases. Rraynex applies controlled pelletization and coating processes to produce uniform multiparticulates suitable for capsule filling, sachets, and other dosage-form development programs. Key Features & Benefits: • Dual delayed-release pellet technology. • Controlled coating and dissolution characteristics. • Uniform pellet size and surface properties. • Suitable for capsule and multiparticulate formulations. • Technical support for development, scale-up, stability, and regulatory documentation. Additional Information: Rraynex manufactures Dexlansoprazole DDR Pellets, Dexlansoprazole Pellets, Dual Delayed Release Pellets, DDR Pellets, Proton Pump Inhibitor Pellets, PPI Pellets, Enteric Coated Pellets, Gastro Resistant Pellets, Delayed Release Pellets, MUPS Pellets, Capsule Filling Pellets, Pharmaceutical Pellets, Bulk Pharmaceutical Pellets, Dexlansoprazole Pellet Manufacturer, Dexlansoprazole Pellet Supplier, Dexlansoprazole Manufacturer India, Pharmaceutical Exporter, CDMO and Contract Manufacturing solutions.
Dexlansoprazole Pellets formulation considerations
- Controlled pelletization and coating for reproducible dissolution and downstream handling.
- Uniform particle size and morphology suitable for capsule filling and multiparticulate systems.
- Manufactured under WHO-GMP with in-process controls on assay, moisture and related substances.
- Technical support for formulation development, scale-up and regulatory documentation.
Technical specifications are available upon request.
Applications
- Capsule filling and multiparticulate dosage forms (including MUPS where applicable).
- Pharmaceutical formulation and commercial manufacturing for Anti-Ulcerant (Ppls) therapies.
- CDMO and contract manufacturing programs requiring bulk dexlansoprazole pellets.
Bulk pharmaceutical supply & commercial manufacture
Rraynex operates as a pharmaceutical pellets manufacturer and supplier based in India, supporting bulk supply, export and contract manufacturing for Dexlansoprazole Pellets. Supply is available in standard 25/50 kg packaging with batch traceability. Export documentation, DMF/COA access procedures and stability information are provided on request for applicable products.
Contact Rraynex for bulk pellet supply • View manufacturing capabilities
Bulk pharmaceutical supply & product enquiries
Looking to source Dexlansoprazole Pellets in bulk? Rraynex supports pharmaceutical companies seeking Dexlansoprazole Pellets for formulation development, capsule filling and commercial pharmaceutical manufacturing. Buyers can request product specifications, available strengths, technical documentation, samples where applicable, commercial quotations and bulk supply information.
- product specifications
- available strengths
- technical documentation
- samples where applicable
- commercial quotations
- bulk supply information
B2B supply only — not a consumer pharmacy. Pricing available on request for bulk quantities.
Related capabilities
Related products
Technical specifications
- Grade
- IP / BP / USP / EP
- Type
- Pellets
- Category
- Anti-Ulcerant (Ppls)
- Pack size
- 25/50 kg
- Available strengths
- 15%, 17%, 20%, 22.5%
- Certifications
- WHO-GMP, ISO 9001, ISO 14001
Only use specification terms supported by existing product data. Additional technical documentation is available upon request.